Have a personal or library account? Click to login
Expression of Platelet Derived Growth Factor a, Its Receptor, and Integrin Subunit Alpha V in Feline Injection-Site Sarcomas Cover

Expression of Platelet Derived Growth Factor a, Its Receptor, and Integrin Subunit Alpha V in Feline Injection-Site Sarcomas

By: Ishtiaq Ahmed and  Sozmen Mahmut  
Open Access
|Mar 2021

References

  1. 1. Zabielska-Koczywas K,Wojtalewicz A,Lechowski R: Current knowledge on feline injection-site sarcoma treatment. Acta Vet. Scand. 2017, 59: 47, doi:10.1186/s13028-017-0315-y.10.1186/s13028-017-0315-y551336828716129
  2. 2. Martano M,Morello E,Buracco P: Feline injection-site sarcoma: Past, present and future perspectives. Vet. J. 2011, 188: 136-141, doi:https://doi.org/10.1016/j.tvjl.2010.04.025.10.1016/j.tvjl.2010.04.02520510635
  3. 3. Hendrick M,Brooks J: Postvaccinal sarcomas in the cat: Histology and immunohistochemistry. Vet. Pathol. 1994, 31: 126-129.10.1177/0300985894031001218140720
  4. 4. Esplin D,Jaffe M,M cGill L: Metastasizing liposarcoma associated with a vaccination site in a cat. Feline practice 1996:20-23.
  5. 5. Chang HW,Ho SY,Lo HF,Tu YC,Jeng CR,Liu CH,Wang FI,Pang VF: Vaccine-associated rhabdomyosarcoma with spinal epidural invasion and pulmonary metastasis in a cat. Vet. Pathol. 2006, 43: 55-58, doi:10.1354/vp.43-1-55.10.1354/vp.43-1-5516407487
  6. 6. Hendrick MJ. Mesen chymal tumors of the skin and soft tissues. In Tumors in domestic animals, John Wiley & Sons, Inc.: 2016; 10.1002/9781119181200.ch5pp. 142-175.10.1002/9781119181200.ch5
  7. 7. Kass PH,Barnes WG, Jr.,Spangler WL,Chomel BB,Culbertson MR: Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma tumorigenesis in cats. J. Am. Vet. Med. Assoc. 1993, 203: 396-405.
  8. 8. Kass PH,Spangler W L,Hendrick MJ,McGill LD,Esplin DG,Lester S,Slater M,Meyer EK,Boucher F,Peters EM: Multicenter case-control study of risk factors associated with development of vaccine-associated sarcomas in cats. J. Am. Vet. Med. Assoc. 2003, 223: 1283-1292.10.2460/javma.2003.223.128314621215
  9. 9. Esplin D,Bigelow M, McGill L,Wilson S: Fibrosarcoma at the site of a lufenuron injection in a cat. Vet. Cancer Soc. Newsletter 1999, 23: 8-9.
  10. 10. Buracco P,Martano M,Morello E,Ratto A: Vaccine-associated-like fibrosarcoma at the site of a deep nonabsorbable suture in a cat. Vet. J. 2002, 163: 105-107, doi:10.1053/tvjl.2001.0617.10.1053/tvjl.2001.061711749145
  11. 11. Daly MK,Saba CF,C rochik SS,Howerth EW,Kosarek CE,Cornell KK,Roberts RE,Northrup NC: Fibrosarcoma adjacent to the site of microchip implantation in a cat. J. Feline Med. Surg. 2008, 10: 202-205, doi:https://doi.org/10.1016/j.jfms.2007.10.011.10.1016/j.jfms.2007.10.01118313963
  12. 12. McEntee MC,Page R L: Feline vaccine-associated sarcomas. J. Vet. Intern. Med. 2001, 15: 176-182.10.1111/j.1939-1676.2001.tb02308.x
  13. 13. Wilcock B,Wilcock A,Bottoms K: Feline postvaccinal sarcoma: 20 years later. The Can. Vet. J. 2012, 53: 430-434.
  14. 14. Woodward KN: Origi ns of injection-site sarcomas in cats: The possible role of chronic inflammation—a review. ISRN Vet. Sci. 2011, 2011: 210982, doi:10.5402/2011/210982.10.5402/2011/210982365883823738095
  15. 15. Sorensen KC,Kitche ll BE,Schaeffer DJ,Mardis PE: Expression of matrix metalloproteinases in feline vaccine site-associated sarcomas. Am. J. Vet. Res. 2004, 65: 373-379.10.2460/ajvr.2004.65.373
  16. 16. Malhotra B,Schuetz e SM: Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: A review of clinical trial results. Curr. Opin. Oncol. 2012, 24: 419-424, doi:10.1097/CCO.0b013e328353d78d.10.1097/CCO.0b013e328353d78d
  17. 17. Jacobs TM,Poehlman n CE,Kiupel M: Injection-site sarcoma in a dog: Clinical and pathological findings. Case Rep. Vet. Med. 2017, 2017: 4, doi:10.1155/2017/6952634.10.1155/2017/6952634
  18. 18. Katayama R,Huelsme yer MK,Marr AK,Kurzman ID,Thamm DH,Vail DM: Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother Pharmacol 2004, 54: 25-33, doi:10.1007/s00280-004-0780-7.10.1007/s00280-004-0780-7
  19. 19. Lawrence J,Saba C, Gogal R,Lamberth O,Vandenplas ML,Hurley DJ,Dubreuil P,Hermine O,Dobbin K,Turek M: Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells*. Vet. Comp. Oncol. 2012, 10: 143-154, doi:10.1111/j.1476-5829.2011.00291.x.10.1111/j.1476-5829.2011.00291.x
  20. 20. Kilvaer TK,Valkov A,Sorbye SW,Donnem T,Smeland E,Bremnes RM,Busund LT: Platelet-derived growth factors in non-gist soft-tissue sarcomas identify a subgroup of patients with wide resection margins and poor disease-specific survival. Sarcoma 2010, 2010: 751304, doi:10.1155/2010/751304.10.1155/2010/751304
  21. 21. Hynes RO: Integrin s: Bidirectional, allosteric signaling machines. Cell 2002, 110: 673-687.10.1016/S0092-8674(02)00971-6
  22. 22. Takada Y,Ye X,Simo n S: The integrins. Genome Biol. 2007, 8: 215, doi:10.1186/gb-2007-8-5-215.10.1186/gb-2007-8-5-215192913617543136
  23. 23. Barczyk M,Carraced o S,Gullberg D: Integrins. Cell Tissue Res. 2010, 339: 269-280, doi:10.1007/s00441-009-0834-6.10.1007/s00441-009-0834-6278486619693543
  24. 24. Silletti S,Kessler T,Goldberg J,Boger DL,Cheresh DA: Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc. Natl. Acad. Sci. U. S. A. 2001, 98: 119-124, doi:10.1073/pnas.011343298.10.1073/pnas.011343298
  25. 25. Dennis MM,McSporra n KD,Bacon NJ,Schulman FY,Foster RA,Powers BE: Prognostic factors for cutaneous and subcutaneous soft tissue sarcomas in dogs. Vet. Pathol. 2011, 48: 73-84, doi:10.1177/0300985810388820.10.1177/0300985810388820
  26. 26. Meuten DJ. Appendi x: Diagnostic schemes and algorithms. In Tumors in domestic animals, John Wiley & Sons, Inc.: 2016; 10.1002/9781119181200.apppp. 942-978.10.1002/9781119181200.app
  27. 27. Meuten DJ,Moore FM, George JW: Mitotic count and the field of view area: Time to standardize. Vet. Pathol. 2016, 53: 7-9, doi:10.1177/0300985815593349.10.1177/0300985815593349
  28. 28. Jones ML,Bancroft JD,Gamble M: Connective tissues and stains. Theory and practice of histological techniques 2008, 6: 135-160.10.1016/B978-0-443-10279-0.50017-8
  29. 29. Mowry RW: Alcian b lue techniques for the histochemical study of acid carbohydrates. J Histochem Cytochem 1956, 4: 403-407.
  30. 30. Mowry RW: The special value of methods that color both acidic and vicinal hydroxyl groups in the histochemical study of mucins. With revised directions for the colloidal iron stain, the use of alcian blue g8x and their combinations with the periodic acid-schiff reaction*. Ann. N. Y. Acad. Sci. 1963, 106: 402-423, doi:10.1111/j.1749-6632.1963.tb16654.x.10.1111/j.1749-6632.1963.tb16654.x
  31. 31. Ahmed I,Sozmen M: Expression of pdgf-a, pdgfra, integrin subunit alpha v and selectin e is increased in canine cutaneous fibrosarcomas. Biotech. & histochem.: 2020, 1-9, doi:10.1 080/10520295.2020.1832256.
  32. 32. Esplin D,Campbell R: Widespread metastasis of a fibrosarcoma associated with a vaccination site in a cat. Feline practice 1995, 23:13-16.
  33. 33. Hendrick MJ,Shofer FS,Goldschmidt MH,Haviland JC,Schelling SH,Engler SJ,Gliatto JM: Comparison of fibrosarcomas that developed at vaccination sites and at nonvaccination sites in cats: 239 cases (1991-1992). J. Am. Vet. Med. Assoc. 1994, 205: 1425-1429.
  34. 34. Aberdein D,Munday JS,Dyer CB,Knight CG,French AF,Gibson IR: Comparison of the histology and immunohistochemistry of vaccination-site and non-vaccination-site sarcomas from cats in new zealand. N. Z. Vet. J. 2007, 55: 203-207, doi:10.1080/00480169.2007.36769.10.1080/00480169.2007.36769
  35. 35. Couto SS,Griffey SM,Duarte PC,Madewell BR: Feline vaccine-associated fibrosarcoma: Morphologic distinctions. Vet. Pathol. 2002, 39: 33-41, doi:10.1354/vp.39-1-33.10.1354/vp.39-1-33
  36. 36. Hendrick MJ,Goldschmidt MH,Shofer FS,Wang Y-Y,Somlyo AP: Postvaccinal sarcomas in the cat: Epidemiology and electron probe microanalytical identification of aluminum. Cancer Res. 1992, 52: 5391-5394.
  37. 37. Doddy FD,Glickman LT,Glickman NW,Janovitz EB: Feline fibrosarcomas at vaccination sites and non-vaccination sites. J. Comp. Pathol. 1996, 114: 165-174, doi:https://doi.org/10.1016/S0021-9975(96)80005-3.10.1016/S0021-9975(96)80005-3
  38. 38. Diep AN,Fleis RI: Pathology in practice. Widespread, metastatic liposarcoma and moderate, acute, diffuse centrilobular hepatic necrosis. J Am Vet Med Assoc 2012, 240: 391-393, doi:10.2460/javma.240.4.391.10.2460/javma.240.4.39122309010
  39. 39. Ahmed I, Sozmen M: Proliferating cell nuclear antigen expression in canine and feline spontaneous and injection-site fibrosarcomas. Pak. Vet. J. 2020, 40: 531-533.10.29261/pakvetj/2020.019
  40. 40. Hendrick MJ,Goldschmidt MH: Do injection site reactions induce fibrosarcomas in cats? J. Am. Vet. Med. Assoc. 1991, 199: 968.
  41. 41. Macy DW,Hendrick MJ: The potential role of inflammation in the development of postvaccinal sarcomas in cats. Vet. Clin. North Am. Small Anim. Pract. 1996, 26: 103-109, doi:https://doi.org/10.1016/S0195-5616(96)50009-4.10.1016/S0195-5616(96)50009-4
  42. 42. Srivastav A,Kass PH,McGill LD,Kent MS,Farver TB: Methodologic approaches to histologically distinguishing vaccine versus nonvaccine-associated sarcomas using validated time and location vaccination histories in cats. ISRN Pathol. 2011, 2011: 6, doi:10.5402/2011/375143.10.5402/2011/375143
  43. 43. Porcellato I,Menchetti L,Brachelente C,Sforna M,Reginato A,Lepri E,Mechelli L: Feline injection-site sarcoma:Matrix remodeling and prognosis. Vet. Pathol. 2017, 54: 204-211, doi:10.1177/0300985816677148.10.1177/030098581667714828005492
  44. 44. Madewell BR,Griffey SM,McEntee MC,Leppert VJ,Munn RJ: Feline vaccine-associated fibrosarcoma: An ultrastructural study of 20 tumors (1996–1999). Vet. Pathol. 2001, 38: 196-202, doi:10.1354/vp.38-2-196.10.1354/vp.38-2-19611280376
  45. 45. Cessna MH,Zhou H,Perkins SL,Tripp SR,Layfield L,Daines C,Coffin CM: Are myogenin and myod1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am. J. Surg. Pathol. 2001, 25: 1150-1157.10.1097/00000478-200109000-0000511688574
  46. 46. Hendrick MJ: Feline vaccine-associated sarcomas: Current studies on pathogenesis. J. Am. Vet. Med. Assoc. 1998, 213: 1425-1426.
  47. 47. Teyssonneau D,Italiano A: Olaratumab for soft tissue sarcoma. Expert Opin. Biol. Ther. 2017, 17: 1019-1025, doi:10.1080/14712598.2017.1339031.10.1080/14712598.2017.133903128691538
  48. 48. Figarella-Branger D,Vagner-Capodano AM,Bouillot P,Graziani N,Gambarelli D,Devictor B,Zattara-Cannoni H,Bianco N,Grisoli F,Pellissier JF: Platelet-derived growth factor (pdgf) and receptor (pdgfr) expression in human meningiomas: Correlations with clinicopathological features and cytogenetic analysis. Neuropathol. Appl. Neurobiol. 1994, 20: 439-447, doi:10.1111/j.1365-2990.1994.tb00994.x.10.1111/j.1365-2990.1994.tb00994.x7531297
  49. 49. Majumdar K,Radotra BD,Vasishta RK,Pathak A: Platelet-derived growth factor expression correlates with tumor grade and proliferative activity in human oligodendrogliomas. Surg. Neurol. 2009, 72: 54-60, doi:10.1016/j.surneu.2008.10.001.10.1016/j.surneu.2008.10.00119559929
  50. 50. Nejjari M,Hafdi Z,Gouysse G,Fiorentino M,Beatrix O,Dumortier J,Pourreyron C,Barozzi C,D’Errico A,Grigioni WF,Scoazec JY: Expression, regulation, and function of alpha v integrins in hepatocellular carcinoma: An in vivo and in vitro study. Hepatology 2002, 36: 418-426, doi:10.1053/jhep.2002.34611.10.1053/jhep.2002.3461112143051
  51. 51. Felding-Habermann B,Fransvea E,O’Toole TE,Manzuk L,Faha B,Hensler M: Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin. Exp. Metastasis 2002, 19: 427-436.10.1023/A:1016377114119
  52. 52. Hosotani R,Kawaguchi M,Masui T,Koshiba T,Ida J,Fujimoto K,Wada M,Doi R,Imamura M: Expression of integrin alphavbeta3 in pancreatic carcinoma: Relation to mmp-2 activation and lymph node metastasis. Pancreas 2002, 25: e30-35.10.1097/00006676-200208000-0002112142752
  53. 53. Baum O,Hlushchuk R,Forster A,Greiner R,Clezardin P,Zhao Y,Djonov V,Gruber G: Increased invasive potential and up-regulation of mmp-2 in mda-mb-231 breast cancer cells expressing the beta3 integrin subunit. Int. J. Oncol. 2007, 30: 325-332.
  54. 54. Wenk CH,Ponce F,Guillermet S,Tenaud C,Boturyn D,Dumy P,Watrelot-Virieux D,Carozzo C,Josserand V,Coll JL: Near-infrared optical guided surgery of highly infiltrative fibrosarcomas in cats using an anti-alphavss3 integrin molecular probe. Cancer Lett. 2013, 334: 188-195, doi:10.1016/j.canlet.2012.10.041.10.1016/j.canlet.2012.10.04123200675
  55. 55. Bello L,Francolini M,Marthyn P,Zhang J,Carroll RS,Nikas DC,Strasser JF,Villani R,Cheresh DA,Black PM: Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 2001, 49: 380-389; discussion 390, doi:10.1097/00006123-200108000-00022.10.1097/00006123-200108000-0002211504114
DOI: https://doi.org/10.2478/acve-2021-0002 | Journal eISSN: 1820-7448 | Journal ISSN: 0567-8315
Language: English
Page range: 13 - 31
Submitted on: Sep 9, 2020
Accepted on: Feb 18, 2021
Published on: Mar 22, 2021
Published by: University of Belgrade, Faculty of Veterinary Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:

© 2021 Ishtiaq Ahmed, Sozmen Mahmut, published by University of Belgrade, Faculty of Veterinary Medicine
This work is licensed under the Creative Commons Attribution 4.0 License.